HC Wainwright & Co. Reiterates Buy on Tenaya Therapeutics, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Tenaya Therapeutics, maintaining a price target of $18.
October 18, 2024 | 10:50 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Tenaya Therapeutics, maintaining a price target of $18, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a price target by a reputable analyst firm like HC Wainwright & Co. suggests a positive outlook for Tenaya Therapeutics. This can boost investor confidence and potentially lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100